Impact of Frailty on Outcomes in Atrial Fibrillation and HFpEF: Data from TOPCAT Trial

Background Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are frequently comorbid, with each condition exacerbating the other's progression and contributing to poor outcomes. Frailty, a syndrome characterized by vulnerability to stressors, is highly prevalent in AF and HFpEF patients and has been associated with adverse outcomes such as stroke, hospitalization, and mortality. However, the specific prognostic implications of varying degrees of frailty in AF comorbid HFpEF patients remain unclear. This study investigates the relationship between frailty, measured using a deficit accumulation frailty index (FI), and adverse outcomes, particularly stroke, in this patient population. Methods This post hoc analysis of the TOPCAT randomized control trial included 721 patients with AF and HFpEF from the Americas (registered date: Aug. 2006, TOPCAT ClinicalTrials.gov number, NCT00094302.) classified into three groups based on FI: Group 1 (FI <0.3), Group 2 (FI 0.3–0.4), and Group 3 (FI ≥0.4). The primary outcome was stroke, and secondary outcomes included heart failure hospitalization, cardiovascular death, and all-cause mortality. Cox proportional hazards models, adjusted for clinical confounders, and Kaplan-Meier analyses were used to assess the association between frailty status and outcomes. A dose-response relationship was evaluated using restricted cubic splines. Results The median FI score indicated that 97.8% of patients were frail. During a mean follow-up of 36±19 months, stroke incidence was significantly higher in Groups 2 and 3 compared with Group 1 (adjusted HR for Group 2: 5.01 [95% CI, 2.00–12.53]; P=0.001 and Group 3: 6.35 [95% CI, 2.26–17.86]; P<0.001). A linear dose-response relationship between FI and stroke risk was observed. Higher frailty was also associated with increased cardiovascular and all-cause mortality but not significantly with heart failure hospitalization.